Results 51 to 60 of about 22,370 (168)

Vildagliptin: a new oral treatment for type 2 diabetes mellitus

Vascular Health and Risk Management, 2008
Chantal Mathieu, Evy DegrandeDepartment of Endocrinology, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell responsiveness to glucose.
Chantal Mathieu, Evy Degrande
doaj  

Incretin levels 1 month after laparoscopic single anastomosis gastric bypass surgery in non-morbid obese type 2 diabetes patients

Asian Journal of Surgery, 2014
Purpose: Bariatric surgery is an efficient procedure for the remission of type 2 diabetes (T2DM) from morbid obesity. However, in Asian countries, the mean body mass index (BMI) of T2DM patients is about 25 kg/m2.
Myung Jin Kim, Hyeong Kyu Park, Dong Won Byun, Kyo Il Suh, Kyung Yul Hur   +4 more
doaj   +1 more source

Pleiotropic effects of incretins

Indian Journal of Endocrinology and Metabolism, 2012
Drugs that augment the incretin system [glucagon like peptide (GLP) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] represent a novel class of anti-hyperglycemic agents that have shown to improve the health and survival of beta-cells (improvement in postprandial hyperglycemia) and suppress glucagon (improvement in fasting hyperglycemia).
openaire   +3 more sources

Metabolic and Digestive Functions of Glucagon-Like Peptide-1 in Pigs

Folia Veterinaria
Glucagon-like peptide-1 (GLP-1) is a hormone with multiple biological effects that plays a key role in glucose metabolism, digestion, and energy homeostasis.
Čulka Ľubomír, Krepelková Zuzana, Bárdová Katarína, Novotný Jaroslav   +3 more
doaj   +1 more source

Impact of Incretin Mimetics on Thyroid Cancer Among Patients with Type 2 Diabetes: A Retrospective Cohort Time-to-Event Analysis

Pharmacoepidemiology
Background: Incretin mimetics, including glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonist) and dipeptidyl peptidase-4 (DPP-4) inhibitors, have been increasingly utilized for glycemic control in patients with type 2 diabetes (T2D ...
Michael W. Strand, Daniel Chow, Weining Shen, Jonathan H. Watanabe   +3 more
doaj   +1 more source

Incretin hormones and obesity

The Journal of Physiology
Abstract The incretin hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) play critical roles in co‐ordinating postprandial metabolism, including modulation of insulin secretion and food intake.
Constanza Alcaino, Frank Reimann, Fiona M. Gribble   +2 more
openaire   +3 more sources

Luseogliflozin restores GIP responsiveness in diabetic male mice with preserved β‐cell function

Physiological Reports
Impaired glucose‐dependent insulinotropic polypeptide (GIP)‐induced insulin secretion is a characteristic feature of type 2 diabetes, whereas glucagon‐like peptide‐1 (GLP‐1) responsiveness is relatively preserved. Our previous study proposed that chronic
Quan Yingyue, Harumi Takahashi, Norihide Yokoi, Wataru Ogawa, Kenji Sugawara   +4 more
doaj   +1 more source

The molecular mechanisms of incretin resistance in Type 2 Diabetes Mellitus (T2DM)

Nutrition & Diabetes
Incretin hormones, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), serve as crucial mediators of postprandial glucose homeostasis by primarily enhancing glucose-stimulated insulin secretion.
Rawayh Muslim Albaghlany, Abbas Ali Mansour   +1 more
doaj   +1 more source

The incretin-bone axis: molecular mechanisms and clinical implications

Frontiers in Endocrinology
Incretin hormones, primarily glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are key regulators of postprandial glucose homeostasis and exert pleiotropic actions beyond pancreatic β-cell function.
Andrea Muscarà, Federica Bellone, Michela Rossi   +2 more
doaj   +1 more source

Incretin Concepts [PDF]

Diabetes Care, 2010
openaire   +2 more sources